MIMESIS program (EU co-funded for Influenza, HRV, RSV, TB, Zika and triple negative breast cancer
To scale-up its drug-discovery approach, the European Commission has granted ENYO Pharma with an Horizon 2020 Research and Innovation program for its MIMESIS project. The aim is to discover and bring to lead optimization at least 5 original preclinical assets in both infectious and non-infectious disease contexts.
A 10 000 small molecules library designed via a biomimetism-based approach, has been screened in phenotypic assays reflecting 6 diseases linked to oncology, viral respiratory infections (Respiratory Syncityal Virus, Influenza virus, Zika virus and Heart Rate Variability), and neglected diseases (Tuberculosis and Zika Virus).
Promising series (some with submicrocolar activity and no cytotoxicity) are currently under optimization. We are open to collaborations and partnerships to co-develop some of the hits and leads.